Stifel Lifts PT on Insmed Incorporated (INSM) to $208 From $205 – Here’s Why

Insmed Incorporated (NASDAQ:INSM) is one of the best high growth healthcare stocks to buy now. Stifel raised the price target on Insmed Incorporated (NASDAQ:INSM) to $208 from $205 on March 24, reaffirming a Buy rating on the shares. The firm told investors that it believes Phase 3b ENCORE results “should unequivocally establish” Arikayce as the new first-line standard-of-care therapy to treat lung infection caused by nontuberculous mycobacteria-mycobacterium avium complex. It added that the ENCORE results “appear a best-case scenario for Arikayce label expansion efforts.”

Insmed Incorporated (NASDAQ:INSM) reported full-year 2025 total revenues of $606.4 million, including BRINSUPRI revenues of $172.7 million for the year and $144.6 million in Q4. ARIKAYCE delivered $119.2 million in Q4 and $433.8 million for the full year, representing 19% annual growth and exceeding the upper end of guidance. The combination of accelerating commercial uptake and expanding market opportunity suggests that 2026 could mark a pivotal inflection point in revenue visibility and operating leverage.

Insmed Incorporated (NASDAQ:INSM) was founded in 1988. Headquartered in Bridgewater, New Jersey, Insmed is a global biopharmaceutical firm focused on developing and commercializing therapies for patients with rare and serious diseases, with key assets including brensocatib and Treprostinil Palmitil Inhalation Powder.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.